Show simple item record

dc.creatorLi, Lihong
dc.creatorZou, Tengteng
dc.creatorLiang, Min
dc.creatorMezhuev, Yaroslav
dc.creatorTsatsakis, Aristidis Michael
dc.creatorBuha-Đorđević, Aleksandra
dc.creatorLan, Meng
dc.creatorLiu, Fengjie
dc.creatorCai, Tiange
dc.creatorGong, Peng
dc.creatorCai, Yu
dc.date.accessioned2021-06-15T07:37:45Z
dc.date.available2021-06-15T07:37:45Z
dc.date.issued2021
dc.identifier.issn0939-6411
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3911
dc.description.abstractObjective: Our study aimed to find potential biomarkers for drug resistance in liver cancer cells using metabolomics and further to evaluate the potential of psoralen-loaded polymer lipid nanoparticles (PSO-PLNs) to reverse the resistance of cells to doxorubicin. Methods: We used LC-MS-based non-targeted metabolomics, also known as global metabolite profiling, to screen in serum and urine of mice engrafted with a liver cancer cell line sensitive (HepG2/S) or resistant to doxorubicin (HepG2/ADR) for differentially regulated metabolites. We subsequently quantified the abundance of these metabolites in serum and the urine of mice. The mice were engrafted with HepG2 cells resistant against doxorubicin and were treated with I) doxorubicin, II) a combination of doxorubicin and psoralen and III) a combination of doxorubicin and psoralen packed in polymer lipid nanoparticles. Results: Metabolites found to be differentially present in urine of mice engrafted with resistant HepG2 cells were: hippuric acid, hyaluronic acid, pantothenic acid, and betaine; retinoic acid and α-linolenic acid were found to be reduced in serum samples of mice with HepG2 cells resistant to doxorubicin. The targeted analysis showed that the degree of regression of metabolic markers in groups differed: treatment group 2 had stronger degree of regression than treatment group 1 and the negative control group had the smallest, which indicates that the PSO-PLNs have superior properties compared with other treatments. Conclusion: Psoralen reverses drug resistance of liver cancer cells and its efficacy can be increased by encapsulation in polymer lipid nanoparticles.
dc.publisherElsevier B.V.
dc.relationNational Natural Science Foundation of China (grant no. 81173215)
dc.relationthe Science and Technology Program of Guangzhou
dc.relationChina (grant nos. 2014J4500005, 201704030141)
dc.relationthe Science Program of the Department of Education of Guangdong
dc.relationChina (grant no. 2015KGJHZ012)
dc.relationthe Guangzhou Key Research and Development Plan
dc.relationChina (grant no. 202103000091)
dc.relationthe Guangdong Key Lab of Traditional Chinese Medicine Information Technology
dc.relationChina (grant no. 2021B1212040007)
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Pharmaceutics and Biopharmaceutics
dc.subjectNanoparticles
dc.subjectBiomarkers
dc.subjectEncapsulation
dc.subjectLiver cancer
dc.subjectMetabolomics
dc.subjectPsolaren
dc.titleScreening of metabolites in the treatment of liver cancer xenografts HepG2/ADR by psoralen-loaded lipid nanoparticles
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЦаи, Тианге; Цаи, Yу; Гонг, Пенг; Мезхуев, Yарослав; Тсатсакис, Aристидис Мицхаел; Буха Ђорђевић, Aлександра; Ли, Лихонг; Зоу, Тенгтенг; Лианг, Мин; Лан, Менг; Лиу, Фенгјие;
dc.citation.volume165
dc.citation.spage337
dc.citation.epage344
dc.identifier.doi10.1016/j.ejpb.2021.05.025
dc.identifier.scopus2-s2.0-85107332739
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record